Male C57BL/6 mice received the compound at 5 mg/kg/d by gavage on days 0 to 21 (full treatment). Ashcroft fibrotic scores in the early-phase and full-treatment groups were significantly lower than in mice treated with BLM alone. In CE-exposed allergic mice, intranasal treatment with the study compound before CE challenge significantly reduced allergic airway inflammation, reflected by lower total leukocyte, eosinophil, and lymphocyte counts in BAL compared with the CE-administered control group. [2,3]
Gavage treatment and Ashcroft scores in mice
Animal study · Eight-week-old male C57BL/6 mice [2]
Male C57BL/6 mice received the compound at 5 mg/kg/d by gavage on days 0 to 21 (full treatment). Ashcroft fibrotic scores in the early-phase and full-treatment groups were significantly lower than in mice treated with BLM alone.
Conditions shared by the study groups
- Route
- by gavage
- Treatment course
- days 0 to 21 (full treatment)
- A-770041 5 mg/kg/d
- Model: Eight-week-old male C57BL/6 mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: A-770041
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Mice and agents (S2); Materials and methods > BLM-induced lung fibrosis in mice (S12); Results > A-77041 attenuates BLM-induced lung fibrosis in mice (S33, S37); Fig 2 legend (S70, S71, S74, S75)
Ashcroft score: Ashcroft score; comparator: BLM alone — Results > A-77041 attenuates BLM-induced lung fibrosis in mice (S37); Fig 2 legend (S74)
A-770041 5 mg/kg/d · Results > A-77041 attenuates BLM-induced lung fibrosis in mice (S33, S37); Fig 2 legend (S70, S71)
Intranasal pretreatment reduced airway inflammation in CE-exposed mice
Animal study · C57BL/6 mice; CE-exposed allergic mice; n = 6–8/group [3]
In CE-exposed allergic mice, intranasal treatment with the study compound before CE challenge significantly reduced allergic airway inflammation, reflected by lower total leukocyte, eosinophil, and lymphocyte counts in BAL compared with the CE-administered control group.
Conditions shared by the study groups
- Route
- i.n.
- Treatment course
- for 5 consecutive days, 30 min before CE challenge (day 11–15)
- Vehicle
- dimethylsulfoxide
- A-770041 10 mg/kg
- Model: C57BL/6 mice; CE-exposed allergic mice; n = 6–8/group
Methods and source locations
Compound reported in the paper: A-770041
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.1. Animals (S1); 2. Materials and Methods > 2.2. Development of Cockroach Extract (CE)-Induced Allergic Inflammation in Mice (S6, S7); 2. Materials and Methods > 2.3. Experimental Groups (S9, S10, S13, S14); 3. Results > 3.2. Inhibition of LCK Signaling Causes Reduction in Airway Inflammation in CE-Induced Allergic Model of Asthma (S53, S54); Figure 2 legend (S88, S89, S90); Figure 8 legend (S105)
Total leukocytes count in BAL: Total leukocytes count in BAL; comparator: Group C: CE-administered group (CE) — 2. Materials and Methods > 2.3. Experimental Groups (S10); 3. Results > 3.2. Inhibition of LCK Signaling Causes Reduction in Airway Inflammation in CE-Induced Allergic Model of Asthma (S53, S54); Figure 2 legend (S89)
A-770041 10 mg/kg · 2. Materials and Methods > 2.3. Experimental Groups (S9, S10, S14); 3. Results > 3.2. Inhibition of LCK Signaling Causes Reduction in Airway Inflammation in CE-Induced Allergic Model of Asthma (S53, S54)